• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

    2/24/25 11:00:00 AM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email

    HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. 

    Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. 

    Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

    Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience's website. 

    About Harvard Bioscience 

    Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

    For more information, please visit our website at www.harvardbioscience.com.

    Company Contact:

    Jennifer Cote

    Chief Financial Officer

    (508) 893-3120

    Investors Contact:

    Three Part Advisors

    Sandy Martin

    [email protected]

    (214) 616-2207



    Primary Logo

    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings